Vickerman, P; Peeling, RW; Terris-Prestholt, F; Changalucha, J; Mabey, D; Watson-Jones, D; Watts, C (2006) Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania. Sexually transmitted infections, 82 Suppl 5. v38-v43. ISSN 1368-4973

Downloaded from: http://researchonline.lshtm.ac.uk/10624/

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Creative Commons Attribution Non-commercial No Derivatives http://creativecommons.org/licenses/by-nc-nd/2.5/
Rapid Diagnostics

Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania

P Vickerman, R W Peeling, F Terris-Prestholt, J Changalucha, D Mabey, D Watson-Jones, C Watts

See end of article for authors’ affiliations

Correspondence to: Dr Peter Vickerman, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; peter.vickerman@lshtm.ac.uk

Accepted 4 September 2006

Objectives: A study found screening (with rapid plasma reagin (RPR)) pregnant women for maternal syphilis was cost-effective in Mwanza, Tanzania. Recently, four rapid point-of-care (POC) syphilis tests were evaluated in Mwanza, and found to have reasonable sensitivity/specificity. This analysis estimates the relative cost-effectiveness of using these POC tests in the Mwanza syphilis screening intervention.

Methods: Empirical cost and epidemiological data were used to model the potential benefit of using POC tests instead of RPR. Reductions in costs relating to training, supplies, and equipment were estimated, and any changes in impact due to test sensitivity were included. Additional modelling explored how the results vary with prevalence of past infection, misclassified RPR results, and if not all women return for treatment.

Results: The cost-effectiveness of using POC tests is mainly dependent on their cost and sensitivity for high titre active syphilis (HTAS). Savings due to reductions in training and equipment are small. Current POC tests may save more disability-adjusted life years (DALYs) than the RPR test in Mwanza, but the test cost needs to be <US$0.63 to be as cost-effective as RPR. However, the cost-effectiveness of the RPR test worsens by 15% if its HTAS sensitivity had been 75% instead of 86%, and by 25–65% if 20–40% of women had not returned for treatment. In such settings, POC tests could improve cost-effectiveness. Lastly, the cost-effectiveness of POC tests is affected little by the prevalence of syphilis, false RPR-positives, and past infections.

Discussion: Although the price of most POC tests needs to be reduced to make them as cost-effective as RPR, their simplicity and limited requirements for electricity/equipment suggest their use could improve the coverage of antenatal syphilis screening in developing countries.

Many developing countries continue to have high syphilis prevalences, with maternal syphilis contributing to substantial perinatal morbidity and mortality worldwide. However, even though antenatal syphilis screening can avert these adverse pregnancy outcomes, and is cost-effective, less than 40% of women attending antenatal services in sub-Saharan Africa receive syphilis screening and treatment.

The low screening and treatment coverage is partly due to limitations of the rapid plasma reagin (RPR) test: it is only useable on serum, requires refrigeration, and has low accuracy in settings with insufficient training or facilities. In addition, long delays between testing and treatment due to batch testing, waiting for serum to separate, or sending tests to central laboratories result in many women not returning/staying for treatment.

In light of this, the Sexually Transmitted Diseases Diagnostics Initiative (SDI) in the World Health Organization (WHO) has promoted the development, evaluation and application of simple rapid point-of-care (POC) tests for diagnosing syphilis in resource-constrained settings. In so doing, it was hoped a test would be developed that could help increase the coverage of antenatal screening and treatment in sub-Saharan Africa.

In 2002, six commercially available POC tests were evaluated by SDI. The evaluated tests were similar to treponemal tests (Treponema pallidum haemagglutination assay (TPHA) or Treponema pallidum particle agglutination assay (TPPA)) in that they are highly specific, but once positive, they remain so for life. RPR, in contrast, mainly detects syphilis infection, but is not very specific. However, there are a number of advantages to the new POC tests when compared to RPR and/ or TPHA/TPPA: they require less or no equipment, minimal training and support, are easier to read, remain stable at room temperature, and can be used on whole blood. This has raised the question of whether these more expensive POC tests could improve existing antenatal syphilis screening programmes.

A previous study in Mwanza, Tanzania, found screening (with RPR) and treating pregnant women for maternal syphilis was highly cost-effective for averting adverse birth outcomes. To explore the potential role of POC tests in antenatal syphilis screening interventions, this paper uses data from this study and an SDI evaluation of four syphilis POC tests in Mwanza to model the cost-effectiveness of using POC tests in this intervention. The model first compared the projected cost-effectiveness of using POC tests with the current RPR screening strategy used in Mwanza, and then explored how the results would vary in settings: with different levels of past infection; where the RPR test is less accurate; or where fewer women receive treatment due to delays between testing and treatment.

Methods

Cost-effectiveness of intervention with RPR test

From July 1998 to June 1999, 9713 women were screened for maternal syphilis at the antenatal clinic in Mwanza, of which 696 (7.2%) were RPR positive and treated. The number of women treated for high titre active syphilis (HTAS) (RPR ≥1:8 and TPHA positive), the only stage shown to be associated with adverse birth outcomes in this setting, was estimated to be 187. However, 30 cases were missed due to the clinic RPR results.

Abbreviations: ANC, antenatal clinic; DALY, disability-adjusted life year; HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin; SDI, Sexually Transmitted Diseases Diagnostics Initiative; TPHA, Treponema pallidum haemagglutination assay; TPPA, Treponema pallidum particle agglutination assay; WHO, World Health Organization

www.stijournal.com
test having a lower sensitivity for HTAS (86.2%) than the laboratory based RPR test used to assess its accuracy.21 The impact of the intervention was estimated in terms of disability-adjusted life years (DALYs) saved, where DALYs are defined as the sum of years of life lost due to premature mortality and years lived with disability adjusted for severity. Based on the detailed calculations by Terris-Prestholt et al20 and only considering adverse birth outcomes, this intervention saved 1321 DALYs (7.1 DALYs saved per HTAS case treated) if stillbirth is considered a full life lost and the Tanzanian life expectancy is used, at an economic cost of US$12.0 per DALY saved (2005 US$). In this analysis, modelling is used to estimate how the cost-effectiveness of this intervention would have changed if they had used syphilis POC tests over this period.

Effectiveness of intervention with POC test

This study only considers the impact achieved from averting adverse birth outcomes. For this reason, and because only HTAS has been shown to be associated with adverse birth outcomes in this setting,20 the impact analysis is only concerned with the number of HTAS treated when different POC tests are used. In Mwanza, some HTAS cases were not treated because of the reduced sensitivity of the clinic RPR test.15 If the TPHA test had been used, then all HTAS cases could have been diagnosed and treated.20 As with the TPHA test, all available syphilis POC tests are treponemal specific, but have reduced sensitivity compared to the TPPA/TPHA test when used on serum.16 If the sensitivity (Sr) and specificity (Sp) of the POC test compared to TPHA is known, the number of women that would test positive with a POC test (Nd) can be estimated from the number positive with the TPHA test (NTPHA):

\[
Nd = N_{TPHA} \times S_{r}(1 - S_{p})(N - N_{TPHA}) \tag{Equation 1}
\]

where \(N\) is the number of women screened. If the ratio between the TPHA and RPR prevalence is known (\(h\)) then the number that will test positive with a POC test can be estimated from the number testing RPR positive (N_RPR) in laboratory conditions by adapting equation 1:

\[
Nd = N_{RPR} \times S_{r}(1 - S_{p})(N - N_{RPR}) \tag{Equation 2}
\]

Because of their reduced sensitivity, POC tests may not diagnose all HTAS cases, with the number positive (Nd_H) being:

\[
Nd_{H} = N_{H}^{HI} \times S_{r}^{HI} \tag{Equation 3}
\]

where \(N_{H}^{HI}\) is the number of HTAS cases in the screened population and \(S_{r}^{HI}\) is the sensitivity of the POC test for HTAS. Because all RPR positive women were treated by the Mwanza intervention, equations 2 and 3 can be used to estimate the number of women and HTAS cases that would have been treated with the POC test in Mwanza. Using the data presented by Terris-Prestholt et al20 on the DALYs saved per HTAS case treated (DALY_H), this can then be used to estimate the DALYs saved.

Cost of intervention with POC test

From the study by Terris-Prestholt et al,4 a cost function for the total economic cost of the existing intervention using RPR tests can be obtained:

\[
\text{COST}_{RPR} = ST + (E_{i} + E_{e} + E_{j}) + T + (\Delta_{i} + \Delta_{j} + \Delta_{k}) + (P_{i} + P_{e} + P_{j}) + R \tag{Equation 4}
\]

where all variables are defined in table 1. This cost function was adapted to model the costs of using POC tests (2005 US$). The model assumed the following aspects of the screening intervention would have changed if POC tests had been used: lab personnel would have required less training; less or no equipment would have been needed; and the number of women treated would have changed depending on the sensitivity/specificity of the POC tests. Therefore, the cost of using POC tests (COSTr) is estimated as:

\[
\text{COST}_{r} = ST + (E_{i} + E_{e} + E_{j}) + T + (\Delta_{i} + \Delta_{j} + \Delta_{k}) + (P_{i} + P_{e} + P_{j}) + R + \text{C}_{\text{drug}} \tag{Equation 5}
\]

where most parameters are defined as before, although \(E_{i}\) and \(E_{j}\) are not needed because POC tests do not require a shaker or fridge, and \(\Delta_{i}\) and \(\Delta_{j}\) are the test and drug costs when using POC tests:

\[
\Delta_{i} = C_{d} N(1 + \delta W) \tag{Equation 6}
\]

\[
\Delta_{j} = C_{d\text{drug}} [N_{PPR}((1 - S_{r})(N - N_{PPR}) + (1 - S_{p})(N - N_{PPR}))] \tag{Equation 7}
\]

where \(C_{d\text{drug}}\) is the penicillin cost per woman treated, \(C_{d}\) is the POC test cost, and \(\delta W\) is the relative wastage of POC tests.

Model parameters

The model was mainly parameterised using data from three studies undertaken in Mwanza, with uncertainty ranges being assigned to most model inputs (table 1). Cost and intervention output data were obtained for 1998–1999 from Terris-Prestholt et al.14 Data on the accuracy of the clinic RPR test compared to the POC test undertaken at a reference laboratory (table 1), and the number of screened women that would have tested positive with a laboratory based RPR or TPHA test, were obtained from a prospective cohort study undertaken in 1997–1999.1 21

Lastly, sensitivity/specificity estimates for the four syphilis POC tests when compared to the TPPA test undertaken in a laboratory setting were obtained from an evaluation of these tests undertaken in Mwanza in 2004 (table 1 and appendix 1: to view appendices 1–6 visit the STI website—http://www.stijournal.com/supplemental). The tests were evaluated on blood in an antenatal clinic (ANC) setting and on blood and serum in a laboratory setting. The ANC results were used to estimate the impact of using POC tests on blood, and because of a lack of other data the laboratory results were used to estimate the impact on serum. The sensitivity of the tests for HTAS was also evaluated, but only on 13–20 HTAS samples. Table 1 also includes the current WHO procurement cost for the POC tests. The POC tests were also assumed to need less training and supply deliveries, and no centrifuge was needed if the tests were used on whole blood.

Cost-effectiveness of intervention with POC test

Using equations 3 and 5, the cost-effectiveness of using a specific POC test (CEr) can be estimated by dividing the estimated cost of the intervention while using that POC test by projections of the DALYs saved from averting adverse birth outcomes:

\[
CE_{r} = \frac{\text{COST}_{r}}{N_{H}^{\text{DALYH}}} \tag{Equation 8}
\]

Because of uncertainty in many model inputs, an uncertainty analysis was undertaken on the projected cost (COSTH) and impact (Nh_H) of using each POC test. Uniform distributions were associated with the uncertainty intervals for most model parameters except the sensitivity and specificity of the POC tests which were assumed to be normally distributed. For each test, random sampling of the parameter uncertainty ranges was used to obtain 500 parameter sets. These produced paired estimates for the impact and cost of the intervention. The distribution obtained was used to obtain uncertainty bounds for the intervention’s cost-effectiveness, which was compared to the cost-effectiveness of the RPR test.4 A multi-linear regression analysis was then undertaken to determine which parameters contributed most to the uncertainty in the cost-effectiveness projections.
Table 1  Model parameters for estimating the cost-effectiveness of the POC test. Cost estimates are in 2005 US$

<table>
<thead>
<tr>
<th>Model parameters</th>
<th>Symbol</th>
<th>Value used</th>
<th>Reference/source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost parameters for RPR intervention</td>
<td>ST</td>
<td>$760.0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>E&lt;sub&gt;i&lt;/sub&gt;</td>
<td>$111.3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>E&lt;sub&gt;f&lt;/sub&gt;</td>
<td>$171.8</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>$69.0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>$125.9</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Δ&lt;sub&gt;0&lt;/sub&gt;</td>
<td>$409.2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Δ&lt;sub&gt;1&lt;/sub&gt;</td>
<td>$3640.7</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Δ&lt;sub&gt;2&lt;/sub&gt;</td>
<td>$4509.0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>P&lt;sub&gt;y&lt;/sub&gt;</td>
<td>$2156.3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>P&lt;sub&gt;a&lt;/sub&gt;</td>
<td>$3720.4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>$158.0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>COST&lt;sub&gt;RPR&lt;/sub&gt;</td>
<td>$15,831.2</td>
<td>4</td>
</tr>
<tr>
<td>Cost per POC test</td>
<td>C&lt;sub&gt;r&lt;/sub&gt;</td>
<td>Bioline $0.47, Syphchek and Visited $0.75, Determine $1.00</td>
<td>Cost through WHO in 2005</td>
</tr>
<tr>
<td>Cost of penicillin per woman treated</td>
<td>C&lt;sub&gt;drug&lt;/sub&gt;</td>
<td>$0.426</td>
<td>Cost for 1998 inflated to 2005*</td>
</tr>
<tr>
<td>Impact model parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of woman screened from 1998–1999</td>
<td>N</td>
<td>9713</td>
<td>4</td>
</tr>
<tr>
<td>Number of screened women positive with RPR test at ANC clinic from 1998–1999</td>
<td></td>
<td>696</td>
<td>4</td>
</tr>
<tr>
<td>Estimated number of women positive with RPR test at reference laboratory clinic</td>
<td>N&lt;sub&gt;RPR&lt;/sub&gt;</td>
<td>1021</td>
<td>Estimated using clinic RPR test sensitivity (61.8%) and specificity (99.3%) from cohort study (see appendix 1)</td>
</tr>
<tr>
<td>Sensitivity of RPR test used at clinic for HTAS</td>
<td>S&lt;sub&gt;TPHA&lt;/sub&gt;</td>
<td>86.2%</td>
<td>3, 21</td>
</tr>
<tr>
<td>Sensitivity of syphilis POC tests:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For all syphilis</td>
<td>S&lt;sub&gt;i&lt;/sub&gt;</td>
<td>45.8–97.1%</td>
<td>See appendix 1 for more details</td>
</tr>
<tr>
<td>For HTAS</td>
<td>S&lt;sub&gt;H&lt;/sub&gt;</td>
<td>64.0–100%</td>
<td>See appendix 1 for more details</td>
</tr>
<tr>
<td>Specificity of syphilis POC tests</td>
<td>S&lt;sub&gt;p&lt;/sub&gt;</td>
<td>93.4–99.9%</td>
<td>See appendix 1 for more details</td>
</tr>
<tr>
<td>Ratio of TPHA/TPHA to RPR prevalence when tests undertaken in reference laboratory</td>
<td>t</td>
<td>95.5% (85–107%)</td>
<td>Estimated from cohort study (see appendix 2)</td>
</tr>
<tr>
<td>Whether they need centrifuge?</td>
<td>δE</td>
<td>0 if use blood, 1 if use serum</td>
<td>Assume less training needed for POC test because simpler to use and diagnose</td>
</tr>
<tr>
<td>Relative time needed for training compared to RPR test</td>
<td>δT</td>
<td>50–100%</td>
<td>53 requisitions done per year for RPR. Less needed for POC tests because no fridge needed and stable for &gt;1 year</td>
</tr>
<tr>
<td>Relative number of requisitions needed for POC test</td>
<td>δR</td>
<td>10–50%</td>
<td></td>
</tr>
<tr>
<td>Relative amount of wastage</td>
<td>δW</td>
<td>0–5%</td>
<td></td>
</tr>
</tbody>
</table>

ANC, antenatal clinic; HTAS, high titre active syphilis; POC, point-of-care; RPR, rapid plasma reagin; TPHA, Treponema pallidum haemagglutination assay; TPPA, Treponema pallidum particle agglutination assay.

To view appendices 1 and 2 visit the STI website—http://www.sti.bmj.com/supplemental

Threshold cost of POC test

The threshold cost (C<sub>r</sub>*) at which a POC test becomes as cost-effective as the RPR test can be obtained from equation 8 to give (see appendix 3 for the derivation):

\[ C^* = \frac{1}{N(1+δW)} \left[ \frac{S^{TPHA}_{RPR} \cdot COST_{RPR} - \left( COST_r - Δ_0 \right)}{S^{TPHA}_{RPR}} \right] \]  

Equation 9

For each POC test, the cost-threshold was calculated for different HTAS sensitivities while other parameters were varied to obtain the lowest cost-threshold at that sensitivity.

Sensitivity analysis to generalise to other settings

To generalise the results of this analysis to other settings, the effect of variations in key parameters on the cost-effectiveness of using the RPR or Bioline test (on blood) was explored.

Firstly, many women screened with the RPR test do not receive treatment at their initial visit<sup>11-12</sup> 22 or do not wait long enough for treatment, and so the cost-effectiveness of the RPR test was estimated for different return rates (60–80%).<sup>16</sup> 19 21 23 Secondly, because of the difficulty in interpreting RPR test results in clinic settings<sup>47 13 14</sup> and the frequent occurrence of RPR biological false positives,<sup>13 17 24 25</sup> the cost-effectiveness of the RPR test was estimated for different sensitivities to HTAS (75–100%).<sup>11 14</sup> and for different prevalences of biological false positives (N<sub>RPR</sub> was varied between 563–1301<sup>13 17</sup>). In contrast, the cost-effectiveness of the POC test was estimated for different prevalences of old infection by varying the ratio t between 104–188%.<sup>17 24 25</sup> Lastly, the cost-effectiveness of both tests was estimated for a wide range of syphilis prevalences (5–21%).

The combined effect of these sensitivity analyses on the cost-threshold for each POC test was analysed by incorporating the return rate for the RPR test into equation 9.

RESULTS

Cost-effectiveness of POC tests

The estimated cost-effectiveness of using the four syphilis POC tests on whole blood or serum are shown in table 2. The results show that all POC tests, except the Determine test, will on average result in more DALYs saved from averting adverse birth outcomes than the RPR test. This is due to their higher sensitivity for HTAS. However, because of the high cost of each POC test, they all result in higher costs, about 6% greater with Bioline test, 21–23% with Visitect and Syphcheck tests, and 36–39% with Determine test. This results in all POC tests, except Bioline, being less cost-effective than the RPR test (ranging from 15–41% higher cost per DALY saved than RPR). In contrast, although our projections suggest the Bioline test is on
average more cost-effective than RPR, 49% of the simulations from the uncertainty analysis suggest otherwise (when used on blood). This is highlighted in appendix 4, which shows the incremental (additional) cost and effectiveness of each POC test relative to the RPR test from the uncertainty analysis. The plots show that there is substantial uncertainty in the incremental impact of the POC tests, but little variation in the incremental cost.

When a multi-linear regression analysis was undertaken on the input and output from each uncertainty analysis, the variability in the cost-effectiveness of each POC test was found to be mainly dependent on the uncertainty in the sensitivity of the POC tests for HTAS. This is illustrated in fig 1, and shows that for each 5% increase in the sensitivity of the POC tests there is an approximate $1 improvement in their cost-effectiveness ratio.

Cost-effectiveness of RPR and POC tests in other settings

A sensitivity analysis was undertaken to explore how the cost-effectiveness of the RPR or POC test changes between settings. The results showed that the prevalence of syphilis, past infections, or PPR false positives has little effect on the cost-effectiveness projections. In contrast, the cost-effectiveness of the RPR test worsens by 15% if its sensitivity for HTAS had been 75% instead of 86%, and by 25–65% if 20–40% of women had not returned for treatment. In these two scenarios, the Bioline POC test is highly likely to be more cost-effective than the RPR test, whereas the other POC tests will only be more cost-effective if the return rate for treatment is towards the lower end of the range considered or their sensitivity for HTAS is towards the high end of the estimated confidence intervals. In contrast, if the RPR test’s sensitivity for HTAS had been 100% then the cost-effectiveness of the RPR test would have improved by 14%. In this situation, the POC tests will only be as cost-effective as the RPR test if they are much cheaper than their current cost, or not all women return for treatment with the RPR test. Appendix 6 shows how the cost-effectiveness of using the RPR or Bioline test changes for these specific scenarios.

Cost thresholds for POC tests

The results in fig 1 show that at current prices only the cheapest POC test (Bioline) could be as cost-effective as the RPR test in Mwanza. Indeed, if they are 100% sensitive for HTAS, the cost of the POC tests has to be less than $0.63 for their cost-effectiveness to be similar to the RPR test. However, if the sensitivity of the POC tests is only 85%, then even the Bioline test would have to be at least $0.13 cheaper than its current cost ($0.47). Appendix 5 shows the threshold costs for each POC test, and shows that for a specific HTAS sensitivity, the cost-thresholds only vary by $0.04 between tests and whether they are used on blood or serum.

For different POC and RPR test sensitivities and return rates, fig 2 shows the lower-bound cost-thresholds for the POC tests. The dashed line signifies the projections for Mwanza (RPR test sensitivity for HTAS = 86%). The figure shows that for every 5% decrease in the return rate or sensitivity of the RPR test for HTAS, the cost of a POC test can be about $0.10 greater. In contrast, for every 5% decrease in the sensitivity of the POC test for HTAS, its cost has to decrease by about $0.12.

DISCUSSION

This study compared the likely cost-effectiveness of four syphilis POC tests against the cost-effectiveness of the RPR test in an antenatal syphilis screening intervention in Mwanza, Tanzania. Uncertainty in the POC test sensitivity for HTAS resulted in uncertainty in their likely impact and cost-effectiveness. Despite this uncertainty, the model projections suggest that all the POC tests, except Determine, are likely to result in marginally greater impact than the RPR test due to their higher HTAS sensitivity in this setting. However, at

Table 2  Cost-effectiveness per DALY saved (2005 US$) of each POC test using Tanzanian life expectancy. Uncertainty bounds are in brackets

<table>
<thead>
<tr>
<th>POC test</th>
<th>Test done on serum*</th>
<th>Test done on blood†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DALYs saved</td>
<td>Cost/DALY saved</td>
</tr>
<tr>
<td>RPR test</td>
<td>1321</td>
<td>12.0</td>
</tr>
<tr>
<td>Determine (Abbott)</td>
<td>1316 (746–1532)</td>
<td>17.0 (14.3–29.5)</td>
</tr>
<tr>
<td>Visitect (Omega)</td>
<td>1373 (877–1532)</td>
<td>14.3 (12.6–22.4)</td>
</tr>
<tr>
<td>Syphcheck (Qualpro)</td>
<td>1390 (887–1531)</td>
<td>14.1 (12.6–21.9)</td>
</tr>
<tr>
<td>Bioline (Standard)</td>
<td>1430 (1127–1532)</td>
<td>11.8 (10.9–15.0)</td>
</tr>
</tbody>
</table>

*The impact and cost-effectiveness estimates for when the POC test is done on serum use specificity and sensitivity estimates derived from the reference laboratory.
† The impact and cost-effectiveness estimates for when the POC test is done on blood use specificity and sensitivity estimates derived from antenatal clinic.

DALY, disability-adjusted life year; POC, point-of-care; RPR, rapid plasma reagin.

Figure 1  Projected cost-effectiveness (per disability-adjusted life year (DALY) saved in 2005 US$) of each syphilis point-of-care (POC) test for different assumptions about their sensitivity for high titre active syphilis (HTAS). The projections assume that the tests are used on blood in an antenatal clinic setting and the bounds refer to the variability due to the uncertainty in the other parameters. CE, cost-effectiveness; RPR, rapid plasma reagin.
Because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis screening interventions in well-equipped settings with well-trained staff such as Mwanza.

In settings where not all screened women are treated because of delays between testing and treatment, or the RPR test has a lower sensitivity for high titre active syphilis (HTAS) than in Mwanza, then POC tests could improve the cost-effectiveness of maternal syphilis screening interventions. This is likely to include many rural or resource-poor settings.

Because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis interventions to settings that would otherwise be hard to reach due to operational difficulties in using the RPR test.

Key messages

- More studies need to be done evaluating the sensitivity of point-of-care (POC) tests for high titre active syphilis (HTAS). However, if the limited data suggesting POC tests have a high sensitivity for HTAS are correct, POC tests could result in similar numbers of ‘at risk’ women being tested for maternal syphilis.

- Unless the cost of available POC tests reduces to below US$0.63, the rapid plasma reagin (RPR) test is likely to be a more cost-effective option for maternal syphilis screening interventions in well-equipped settings with well-trained staff such as Mwanza.

- In settings where not all screened women are treated because of delays between testing and treatment, or the RPR test has a lower sensitivity for high titre active syphilis (HTAS) than in Mwanza, then POC tests could improve the cost-effectiveness of maternal syphilis screening interventions. This is likely to include many rural or resource-poor settings.

- Because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis interventions to settings that would otherwise be hard to reach due to operational difficulties in using the RPR test.
being used for screening and would normally require confirmatory testing, but given the potential threat for the unborn child treatment is given even when this cannot be done. This is especially important when treatment strategies also invite partners for treatment.

CONCLUSION

More studies need to be done evaluating the sensitivity of POC tests for HTAS. However, if the limited data suggesting POC tests have a high sensitivity for HTAS are correct, POC tests should be considered as an alternative to the RPR test in many settings. In Mwanza, the Bioline, Visitect and Syphcheck tests are all likely to have resulted in more “at risk” women being treated, and the Bioline test would have cost a similar amount per DALY saved. Indeed, the Bioline test is likely to be more cost-effective than the RPR test in settings where either not all screened women are treated, or the RPR test has a lower sensitivity for HTAS than in Mwanza. This is likely to include many settings where maternal syphilis screening currently takes place,6 10–13 15 22 and specifically many rural or resource-poor settings. Alternatively, the RPR test is likely to be a better option in well equipped settings with well trained staff. For the other POC tests to be as cost-effective as the RPR test and competitive with the Bioline test, they need to be at least as cheap as the Bioline test or highly sensitive for HTAS. Lastly, because POC tests are not dependent on expensive equipment or electricity, they could enable the scaling up of maternal syphilis interventions to settings that would otherwise be hard to reach due to operational difficulties in using the RPR test. This is an important advantage of POC tests, and their use in low coverage areas should be seen as an important priority for health providers.

ACKNOWLEDGEMENTS

This research was funded by WHO/TDR and the Welcome Trust. David Mabey, Charlotte Watts, Deborah Watson-Jones and Peter Vickerman also receive funding from the DFID funded AIDS Knowledge Programme. The views expressed are those of the authors and cannot be taken to reflect the official opinion of the London School of Hygiene and Tropical Medicine.

AUTHOR CONTRIBUTIONS

PV participated in the planning of the analysis, collated already published and unpublished data from Mwanza, developed and adapted the impact and cost model for estimating the cost-effectiveness of the POC tests, performed all simulations and sensitivity analysis, interpreted results and wrote the manuscript. FTP, RWP, DM, JC, DWJ and CW all helped in interpreting the model results, and contributed to the manuscript. In addition, FTP, RWP, DM, and CW all helped in planning the analysis, FTP developed the initial cost-effectiveness spreadsheet model, RWP and DM had the initial idea for the study and gave continual expert advice, and JC and DWJ provided published and unpublished data and expertise.

To view appendices 1-6 visit the STI website—http://www.stijournal.com/supplemental

Authors’ affiliations

P Vickerman, T Ferris-Prestholt, J Changalucha, D Mabey, D Watson-Jones, C Watts, London School of Hygiene & Tropical Medicine, London, UK

R W Peeling, Sexually Transmitted Disease Diagnostic Initiative, World Health Organization WHO/TDR, Geneva, Switzerland

Competing interests: none declared

REFERENCES

Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania

P Vickerman, R W Peeling, F Terris-Prestholt, et al.

*Sex Transm Infect* 2006 82: v38-v43
doi: 10.1136/sti.2006.021824

Updated information and services can be found at:
http://sti.bmj.com/content/82/suppl_5/v38.full.html

These include:

**Data Supplement**
"web only appendix"
http://sti.bmj.com/content/suppl/2007/01/11/82.suppl_5.v38.DC1.html

**References**
This article cites 18 articles, 10 of which can be accessed free at:
http://sti.bmj.com/content/82/suppl_5/v38.full.html#ref-list-1

Article cited in:
http://sti.bmj.com/content/82/suppl_5/v38.full.html#related-urls

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Syphilis (485 articles)
- Screening (epidemiology) (610 articles)
- Screening (public health) (610 articles)
- Pregnancy (273 articles)
- Reproductive medicine (800 articles)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/